CPhI Awards 2020 Categories and Criteria.
Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
We are no longer accepting entries for the 2020 CPhI Pharma Awards.
For 2020 the CPhI Pharma Awards will be held online as part of the CPhI: Festival of Pharma. To attend the CPhI Pharma Awards online and watch the winners be announced you will need to register here for the CPhI: Festival of Pharma. The Awards will take place on 13 October at 4pm (CET)
The CPhI Pharma Awards seek to recognise innovation in the Pharmaceutical industry and are open to Pharmaceutical and Biopharmaceutical companies, engaged in the design, development, manufacture, production and distribution of large and small molecule drug products.
All entries for the 2020 CPhI Pharma Awards referred to products, services and initiatives launched in between 1 July 2019 – 30 June 2020 except from Excellence in Pharma: Finished Formulation - see criteria details for the eligibility period relevant to this category only.
In reviewing your entry, the Jury will look for evidence and examples. To strengthen your entry, we encourage you to submit supporting evidence where appropriate, such as:
A new award for 2020 designed to recognise innovation in technologies, products, processes, and services to combat the impact of COVID-19 on individuals, patients, healthcare professionals and communities. Including but not limited to the development and manufacture of potential vaccines, drug products and medical equipment and the introduction of services, solutions and resources to provide support to those effected by the pandemic.
* Given the short timeframes for response to the COVID-19 pandemic, we understand that many products or solutions will not yet have regulatory approval. Please submit as much evidence and support for your entry as is feasibly possible.
Innovation in technologies, products, processes, and services for the development and manufacture of active pharmaceutical ingredients (APIs) including, but not limited to, synthesis, characterization, formulation, scale-up, software and database development, bulk manufacturing.
Innovation in technologies, products, processes, and services related to the formulation of drug products including, but not limited to, excipients, finished dose, OTC, novel software and databases, process development, resolving formulation challenges such as solubility/ bioavailability enhancement, drug targeting or controlled release, solving stability issues such as protein aggregation, etc. Please note: to be eligible for this category, the activity must have taken place between 1 July 2017 and 30 June 2020
Innovation in technologies, products, processes, and services for the manufacture of solid, semi-solid, parenteral, inhalation, or other dosage drugs including, but not limited to, equipment, manufacturing processes, facilities, process controls, and continuous manufacturing.
Innovation in technologies, products, processes, and services for the processing and manufacture of biologic-based drugs including, but not limited to, equipment, raw materials, cell lines, manufacturing processes, facilities, process controls, and continuous biomanufacturing.
Innovation in technologies, products, processes, and services for the analysis and testing of drug substances, raw materials, and drug products in a laboratory on production line setting including, but not limited to, laboratory instruments and equipment, analytical instruments, laboratory software, quality control tools, data integrity systems, and contract laboratory services.
Innovation in technologies, products, processes, and services related to primary and secondary packaging of finished drug forms, and delivery of drug products to patients. Including, but not limited to, inhalers, auto-injectors, vials, syringes, patches, combination products, tamper-proof packaging, child-safety packaging, labelling, intelligent packaging, and fill-finish.
Innovation in technologies, products, processes, and services related delivery of drug products to patients including, but not limited to, inhalers, auto-injectors, vials, syringes, patches, and combination products.
Innovation in digital technologies, products, processes, initiatives and services which drive value in pharmaceutical development and improve patient outcomes. Including but not limited to advanced and predictive analytics, Artificial Intelligence, automation, patient-centric solutions for improved experience and adherence, track and trace, remote monitoring, medical devices and wearables.
Innovation in technologies, products, processes, and services for ensuring the safe handling and tracking of drug substances, raw materials, and finished drug products including, but not limited to, supply chain, audits, temperature-controlled logistics, transport services, track and trace, shipping containers, and distribution channels.
Innovation in contracted services and processes for the bio/pharmaceutical industry including, but not limited to, drug research, development, formulation, scale up, process development, clinical trial manufacturing, drug product manufacturing, API development and manufacturing, laboratory services, and consulting.
This award recognizes sustainable development in the Pharmaceutical industry and innovative initiatives for improving outcomes for patients, employees, the environment and wider community. Including but not limited to, initiatives to minimise environmental impact, waste reduction, energy & utility saving solutions, sustainable and collaborative product development, innovative and sustainable use of resources, social outreach, employee training and mentoring programs, fair employee working policies, diversity and inclusion initiatives.
Innovation in technologies, products, processes, and services designed to aid and ensure that bio/pharma companies comply with standards, rules, and guidance documents established by regulatory authorities including, but not limited to, consulting services, development of consortia and industry groups, reference standards, educational programs, and software and IT, technologies, and equipment.
C-Suite Executives of SME, Large Pharma/Biopharma or service providers are eligible for nomination. Attributes to be considered include, but are not limited to, financial performance, product performance, global reach, leadership skills, management capability, charitable initiatives, sustainability, regulatory compliance, profitability, vision, marketing, acquisitions, corporate strategy, and financing.
Bio/pharmaceutical companies and service providers that develop, produce, manufacture and market pharmaceutical products are eligible to be nominated.
For Sponsorship enquiries:
Tel: +44 (0) 7917 647 859
For entry and general enquiries:
Tel: +44 (0) 20 701 75173